Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

Autor: Isacco Desideri, G. Tonini, Emanuela Magnolfi, L. Pizzuti, Jennifer Foglietta, Marina Elena Cazzaniga, Adamo, Patrizia Vici, Enrico Cortesi, Emanuela Risi, G. D'Auria, Loretta D'Onofrio, Mario Roselli, Isabella Sperduti, N. Tinari, Nicola D’Ostilio, A. Vaccaro, Icro Meattini, Federica Tomao, Giacomo Barchiesi, B Di Cocco, F Cardillo, Enzo Veltri, Claudia Omarini, Mirco Pistelli, Clara Natoli, Carlo Garufi, E. Landucci, M. Mauri, Rosanna Mirabelli, Federico Piacentini, Domenico Corsi, A.F. Scinto, Alice Villa, Alain Gelibter, C. De Angelis, Marco Mazzotta, Gennaro Ciliberto, Claudio Zamagni, Giuseppe Sanguineti, Fiorentino Izzo, Elizabeth H. Baldini, Rossana Berardi, Grr Ricciardi, Maddalena Barba, Ornella Garrone, Ida Paris, Luisa Carbognin, A. Botticelli, Giuseppina Sarobba, Silverio Tomao, Antonio Astone, Lucia Mentuccia, P Del Medico, Lorusso, Daniele Santini, M. Della Giulia, Riccardo Samaritani, Francesco Giotta, Alessandra Cassano, Laura Iezzi, Maria Agnese Fabbri, R De Maria, Eriseld Krasniqi, Raffaele Giusti, Sini, Lorenzo Livi, Ernesto Rossi, Andrea Michelotti, Emilio Bria, A Di Leo, Luca Moscetti, Corrado Ficorella, Antonino Grassadonia, Roberta Sarmiento, Katia Cannita, Filippo Greco, Sandro Barni, Elena Fiorio, Teresa Gamucci, Magri, Antonio Russo, M. De Tursi, N. La Verde, Daniele Generali, Paolo Marchetti

Publikováno v: International Journal of Cancer

We analyzed data from 738 HER2‐positive metastatic breast cancer (mbc) patients treated with pertuzumab‐based regimens and/or T‐DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c744e104d7bb709c3f49904f7a5d8b4
http://hdl.handle.net/11573/1307277

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease

Autor: Paolo Carlini, Alessandra Fabi, Gia Ferretti, B. Di Cocco, Paola Papaldo, Maria Simona Pino, M. Mottolese, C. Nardoni, A. M. Cianciulli, Isabella Sperduti, Francesco Cognetti, S. Di Cosimo, I. Sacchi

Publikováno v: Annals of Oncology. 17:630-636

Purpose: To observe whether in pretreated metastatic breast cancer patients with HER2-positive disease vinorelbine plus trastuzumab can produce different overall response rate (ORR), time to progression (TTP), and overall survival (OS) from women wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0288fd7960c4ddf5b5fce1d7750c78
https://doi.org/10.1093/annonc/mdj110

[New and old procedures in the diagnosis of dubious breast lesions]

Autor: M R, Giovagnoli, A, Bonifacino, T, Pisani, B, Di Cocco, G, Dalfino, V, Petrocelli, A, Vecchione

Publikováno v: Minerva ginecologica. 55(6)

In the last years the detection of early breast cancers (lesions less than one centimetre in diameter, with good prognosis) has consistently increased for the wide application of mammary screening programs. At the same time, an increasing number of r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::291da7bc542faa36403a0acd1f318b2d
https://pubmed.ncbi.nlm.nih.gov/14676738

[A new drug in the therapy of chronic myeloid leukemia: ST1571]

Autor: N, Salesi, G, Bossone, G, Della Longa, B, Di Cocco

Publikováno v: Minerva medica. 94(2)

The therapy of chronic myeloid leukemia, characterized by the presence of the Philadelphia chromosome in the clonal hematopoietic stem cells, has changed dramatically in the last years with the development of a specific inhibitor of the BCR-ABL tyros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3f71ba7a5ec720c8d1c9c846279bcca1
https://pubmed.ncbi.nlm.nih.gov/12858155

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.